Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Targeting fibrosis: mechanisms and clinical trials
M Zhao, L Wang, M Wang, S Zhou, Y Lu… - Signal transduction and …, 2022 - nature.com
Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …
dysregulated wound and connective tissue repair response. Multiple organs can develop …
[HTML][HTML] Mechanisms and disease consequences of nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …
[PDF][PDF] Lean NAFLD: a distinct entity shaped by differential metabolic adaptation
F Chen, S Esmaili, GB Rogers, E Bugianesi… - …, 2020 - Wiley Online Library
Background and Aims Nonalcoholic fatty liver disease (NAFLD) affects a quarter of the adult
population. A significant subset of patients are lean, but their underlying pathophysiology is …
population. A significant subset of patients are lean, but their underlying pathophysiology is …
[HTML][HTML] FXR agonists in NASH treatment
L Adorini, M Trauner - Journal of hepatology, 2023 - Elsevier
The farnesoid X receptor (FXR), a bile acid (BA)-activated nuclear receptor highly expressed
in liver and intestine, regulates the expression of genes involved in cholesterol and bile acid …
in liver and intestine, regulates the expression of genes involved in cholesterol and bile acid …
FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases
EJ Tillman, T Rolph - Frontiers in endocrinology, 2020 - frontiersin.org
The rising global prevalence of obesity, metabolic syndrome, and type 2 diabetes has driven
a sharp increase in non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat …
a sharp increase in non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat …
Bile acids and FXR: novel targets for liver diseases
M Stofan, GL Guo - Frontiers in medicine, 2020 - frontiersin.org
Bile acids (BAs) are evolutionally conserved molecules synthesized in the liver from
cholesterol and have been shown to be essential for lipid homeostasis. BAs regulate a …
cholesterol and have been shown to be essential for lipid homeostasis. BAs regulate a …
Bile acid and receptors: Biology and drug discovery for nonalcoholic fatty liver disease
T Jiao, Y Ma, X Guo, Y Ye, C ** effects of FGF19 and FGF21 from mice to human
E Henriksson, B Andersen - Frontiers in Endocrinology, 2020 - frontiersin.org
FGF19 and FGF21 analogues are currently in clinical development for the potential
treatment of NASH. In Phase 2 clinical trials analogues of FGF19 and FGF21 decrease …
treatment of NASH. In Phase 2 clinical trials analogues of FGF19 and FGF21 decrease …
[HTML][HTML] Recent advances in the digestive, metabolic and therapeutic effects of farnesoid X receptor and fibroblast growth factor 19: from cholesterol to bile acid …
Bile acids (BA) are amphiphilic molecules synthesized in the liver (primary BA) starting from
cholesterol. In the small intestine, BA act as strong detergents for emulsification …
cholesterol. In the small intestine, BA act as strong detergents for emulsification …